MedImmune, LLC - Product Pipeline Review - 2016

  • ID: 3714978
  • Company Profile
  • 164 pages
  • Global Markets Direct
  • Medimmune
1 of 4
MedImmune, LLC - Product Pipeline Review - 2016

Summary

‘MedImmune, LLC - Product Pipeline Review - 2016’, provides an overview of the MedImmune, LLC’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by MedImmune, LLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of MedImmune, LLC
- The report provides overview of MedImmune, LLC including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses MedImmune, LLC’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features MedImmune, LLC’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate MedImmune, LLC’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for MedImmune, LLC
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding MedImmune, LLC’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

MedImmune, LLC Snapshot

MedImmune, LLC Overview

Key Information

Key Facts

MedImmune, LLC - Research and Development Overview

Key Therapeutic Areas

MedImmune, LLC - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

MedImmune, LLC - Pipeline Products Glance

MedImmune, LLC - Late Stage Pipeline Products

MedImmune, LLC - Clinical Stage Pipeline Products

MedImmune, LLC - Early Stage Pipeline Products

MedImmune, LLC - Drug Profiles

MEDI-550

anifrolumab

benralizumab

durvalumab

durvalumab + tremelimumab

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine

moxetumomab pasudotox

tralokinumab

inebilizumab

dusigitumab

INO-3112

mavrilimumab

MEDI-2070

MEDI-3902

MEDI-4893

MEDI-6012

MEDI-7510

MEDI-8852

MEDI-8897

tremelimumab

inebilizumab + MEDI-0680

MEDI-0382

AMG-211

AMP-110

AMP-224

durvalumab + gefitinib

durvalumab + MEDI-0680

durvalumab + MEDI-6383

inebilizumab + rituximab

MEDI-0562

MEDI-0639

MEDI-0680

MEDI-1814

MEDI-1873

MEDI-3617

MEDI-3617 + tremelimumab

MEDI-4166

MEDI-4276

MEDI-4920

MEDI-6383

MEDI-7836

MEDI-8111

MEDI-9197

MEDI-9447

Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma

respiratory syncytial virus vaccine 1

respiratory syncytial virus vaccine 2

MEDI-5117

264-RAD

Biologics for Acute Coronary Syndrome

EVT-770

MEDI-5304

MEDI-9314

Monoclonal Antibody Conjugates to Inhibit DNA Synthesis for Solid and Hematological Tumors

Monoclonal Antibody to Inhibit ILT7 for Systemic Lupus Erythematosus

PRO-391

V-2L2MD

ALM

Monoclonal Antibodies for Cancer

Monoclonal Antibody to Antagonize ECA for Enterobacteriaceae Infections

Recombinant Proteins for Cancer

MedImmune, LLC - Pipeline Analysis

MedImmune, LLC - Pipeline Products by Target

MedImmune, LLC - Pipeline Products by Route of Administration

MedImmune, LLC - Pipeline Products by Molecule Type

MedImmune, LLC - Pipeline Products by Mechanism of Action

MedImmune, LLC - Recent Pipeline Updates

MedImmune, LLC - Dormant Projects

MedImmune, LLC - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

MedImmune, LLC - Company Statement

MedImmune, LLC - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

MedImmune, LLC - Key Manufacturing Facilities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

MedImmune, LLC, Key Information

MedImmune, LLC, Key Facts

MedImmune, LLC - Pipeline by Indication, 2016

MedImmune, LLC - Pipeline by Stage of Development, 2016

MedImmune, LLC - Monotherapy Products in Pipeline, 2016

MedImmune, LLC - Combination Treatment Modalities in Pipeline, 2016

MedImmune, LLC - Partnered Products in Pipeline, 2016

MedImmune, LLC - Partnered Products/ Combination Treatment Modalities, 2016

MedImmune, LLC - Out-Licensed Products in Pipeline, 2016

MedImmune, LLC - Out-Licensed Products/ Combination Treatment Modalities, 2016

MedImmune, LLC - Pre-Registration, 2016

MedImmune, LLC - Phase III, 2016

MedImmune, LLC - Phase II, 2016

MedImmune, LLC - Phase I, 2016

MedImmune, LLC - Phase 0, 2016

MedImmune, LLC - IND/CTA Filed, 2016

MedImmune, LLC - Preclinical, 2016

MedImmune, LLC - Discovery, 2016

MedImmune, LLC - Pipeline by Target, 2016

MedImmune, LLC - Pipeline by Route of Administration, 2016

MedImmune, LLC - Pipeline by Molecule Type, 2016

MedImmune, LLC - Pipeline Products by Mechanism of Action, 2016

MedImmune, LLC - Recent Pipeline Updates, 2016

MedImmune, LLC - Dormant Developmental Projects,2016

MedImmune, LLC - Discontinued Pipeline Products, 2016

MedImmune, LLC, Other Locations

MedImmune, LLC, Subsidiaries

MedImmune, LLC, Key Manufacturing Facilities

List of Figures

MedImmune, LLC - Pipeline by Top 10 Indication, 2016

MedImmune, LLC - Pipeline by Stage of Development, 2016

MedImmune, LLC - Monotherapy Products in Pipeline, 2016

MedImmune, LLC - Combination Treatment Modalities in Pipeline, 2016

MedImmune, LLC - Partnered Products in Pipeline, 2016

MedImmune, LLC - Out-Licensed Products in Pipeline, 2016

MedImmune, LLC - Pipeline by Target, 2016

MedImmune, LLC - Pipeline by Route of Administration, 2016

MedImmune, LLC - Pipeline by Top 10 Molecule Type, 2016

MedImmune, LLC - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll